Clinical Trials Logo

Clinical Trial Summary

This trial is a two-step Phase I/II study comprising: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination (N= up to 30 patients). In the dose escalation part, eligible patients will be treated with a fixed dose of pazopanib and escalating doses of HDM201. Part 2: An extension part to collect preliminary data about the clinical activity of the proposed combination according to the 6M-PFR.


Clinical Trial Description

This trial is a two-step Phase I/II study comprising: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination (N= up to 30 patients). The dose escalation will be conducted according to a sequential and adaptive Bayesian scheme using the method of Time-to-event Continual Reassessment Method (CRM) to guide dose escalation and estimate the Maximum Tolerated Dose. In the dose escalation part, eligible patients will be treated with a fixed dose of pazopanib (800 mg/d) and escalating doses of HDM201: 60 mg (starting dose); 80 mg; 100 mg; 120 mg. For a safety reason, a dose level of 40 mg is included in case that the first dose level is found to be toxic. In addition, decrease of pazopanib dosing to 600 mg/d could be appropriate following protocol amendment. To ensure adequate patient safety during the dose escalation part, there will be a 3-day delay between the first and subsequent patients enrolled in each DL cohort to maximize the safety of enrolled patients. No intra-patient dose escalation is allowed. Part 2: An extension part to collect preliminary data about the clinical activity of the proposed combination according to the 6 months Progression Free Rate (6M-PFR). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05180695
Study type Interventional
Source Centre Leon Berard
Contact
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date January 2022
Completion date July 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05043649 - Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Phase 1
Recruiting NCT05146440 - Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor Phase 1/Phase 2
Recruiting NCT04874311 - Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma Phase 2
Not yet recruiting NCT05099666 - Lurbinectedin + Doxorubicin In Leiomyosarcoma Phase 1/Phase 2
Not yet recruiting NCT04780464 - A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma Phase 3
Recruiting NCT04757337 - Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients Phase 3
Recruiting NCT04705818 - Combining Epigenetic And Immune Therapy to Beat Cancer. Phase 2
Active, not recruiting NCT03022448 - Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)
Not yet recruiting NCT05182164 - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Phase 2
Not yet recruiting NCT05154630 - Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors Phase 1/Phase 2